

Remarks

Claims 31-33, 35, and 37-40 are canceled herewith as being drawn to a non-elected invention. Applicants reserve the right to pursue the subject matter of the canceled claims in one or more continuing applications.


New claims 41-58 are added herewith. The new claims fall within the subject matter of elected Group I. The new claims were included in the text of the application as filed as original claims 2, 3, 4, 5, 8, 9, 12, 13, 14, 16, 17, 18, 19, 25, 26, 28, 29, and 30; however, a preliminary amendment initially was submitted to reduce the filing fees for these additional claims.

Applicants submit herewith the new claims and request that the Examiner consider these new claims in assessing the patentability of each of the pending claims.

Summary

If any other information is needed, please contact the undersigned attorney by phone (617-720-3500, Ext. 343) to expedite the further prosecution of this patent application.

WOLF, GREENFIELD & SACKS, P.C.

By:   
Elizabeth R. Plumer, Reg. No. 36,637  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, MA 02210  
Tel. (617)720-3500

Docket No. L0559/7001  
Date: January 29, 2001  
X02/13/01

- (a) a biotin conjugate comprising
    - (i) a biotin covalently coupled to
    - (ii) an agent having a pharmacological activity; and
  - (b) a pharmaceutically acceptable carrier, wherein the
- 5 pharmaceutically acceptable carrier is suitable for parenteral administration.
41. The composition of claim 1, wherein the composition is lyophilized.
42. The composition of claim 1, further comprising a pharmaceutically acceptable carrier.
- 10 43. The composition of claim 42, wherein the pharmaceutically acceptable carrier is acceptable for a mode of delivery selected from the group consisting of: intradermal delivery, intramuscular delivery, intraperitoneal delivery, intravenous delivery, subcutaneous delivery, and controlled release delivery.
44. The composition of claim 1, wherein the biotin is selected from the
- 15 group consisting of L-biotin, D-biotin and derivative thereof.
45. The composition of claim 7, wherein the chemokine is selected from the group consisting of the chemokines of Table 1.
46. The composition of claim 7, wherein the chemokine has a carboxyl terminus and the biotin is covalent attached to the carboxyl terminus of the
- 20 chemokine.
47. The composition of claim 1, wherein the biotin is covalently coupled to the pharmacologically active agent via a linker molecule.
48. The composition of claim 1, wherein the complex has a half-life ranging from about 15 minutes to about 1 hour in the presence of supra physiological
- 25 levels of biotin.
49. The composition of claim 1, wherein the anti-biotin antibody has an affinity constant ranging from about 1.0 to about 100.0 nanomolar.
50. The composition of claim 1, wherein the anti-biotin antibody is selected from the group consisting of an intact antibody, and an antibody fragment.
- 30 51. The composition of claim 1, wherein the anti-biotin antibody is a human antibody or fragment thereof.

52. The composition of claim 1, wherein the anti-biotin antibody has a subclass selected from the group consisting of a IgG1 subclass, and an IgG3 subclass.

53. The composition of claim 1, wherein the anti-biotin antibody  
5 comprises a therapeutic agent attached thereto.

54. The composition of claim 1, wherein the complex has a half-life of from one day to one month in vivo.

55. The composition of claim 1, wherein the complex has a half-life of from one week to two weeks in vivo.

10 56. The composition of claim 27, wherein the therapeutically effective amount of biotin is from about 100  $\mu$ g to about 100 mg.

57. The composition of claim 27, wherein the therapeutically effective amount of biotin is from about 100  $\mu$ g to about 10 mg.

58. The composition of claim 27, wherein the therapeutically effective  
15 amount of biotin is from about 1 mg to about 10 mg.

---